Finanzen von Mineralys Therapeutics Inc (MLYS)MLYSMineralys Therapeutics Inc

Evaluating the bottom line, Mineralys Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -80.88%, provide a clear picture of how effectively MLYS converts its operational activities into shareholder value.

In the context of the broader market, MLYS competes directly with industry leaders such as MRVI and ALMR. With a market capitalization of $1.84B, it holds a significant position in the sector. When comparing efficiency, MLYS's gross margin of N/A stands against MRVI's 40.14% and ALMR's 60.21%. Such benchmarking helps identify whether Mineralys Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company has been experiencing substantial losses, with a net income of -241 million USD in Q2 2026 and an EPS of -2.85, indicating ongoing financial struggles. The forward P/E ratio is 0, suggesting no earnings are expected in the near term.